



  



























<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang='en'>
<head>  
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <meta name="viewport" content="width=994, user-scalable=yes" /> 
  <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
    <meta name="robots" content="noindex,nofollow"/>
    <title>Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial - Tabular View - ClinicalTrials.gov</title>
    <link href="/ct2/show/record/NCT00041938" rel="canonical"/>
  
  <link rel="shortcut icon" href="/ct2/html/images/favicon.ico" />
	<link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-144x144.png' sizes='144x144'>
	<link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-114x114.png' sizes='114x114'>
	<link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-72x72.png'   sizes='72x72'>
	<link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-precomposed.png' >
	<link rel='apple-touch-icon-precomposed' href='/apple-touch-icon.png' >

  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/superfish.css" media="screen" />
  <link href="/ct2/html/ct3/css/base.css" rel="stylesheet" type="text/css" />

	<link rel="stylesheet" href="/ct2/html/ct3/css/print.css" type="text/css" media="print" />
	
	

     <!--[if lte IE 7]>
           <link href="/ct2/html/ct3/css/target-IE7-and-below.css" rel="stylesheet" type="text/css">
    <![endif]-->

<link href="/ct2/html/ct3/css/trial-record.css" rel="stylesheet" type="text/css" />
<link href="/ct2/html/ct3/css/ct2Header.css" rel="stylesheet" type="text/css" />


    <script type="text/javascript" src="/ct2/html/ct3/js/jquery-1.6.4.min.js"></script>
    <script type="text/javascript" src="/ct2/html/ct3/js/superfish.js"></script>
    <script type="text/javascript" src="/ct2/html/ct3/js/supersubs.js"></script>
    <script type="text/javascript" src="/ct2/html/ct3/js/hoverIntent.js"></script>
    <script type="text/javascript" src="/ct2/html/ct3/js/jquery.cookie.js"></script>
    <script type="text/javascript" src="/ct2/html/ct3/js/jquery.fontscale.js"></script>

    <script type="text/javascript" src="/ct2/html/images/frame/ct.js"></script>
    <script type="text/javascript" src="/ct2/html/ct3/js/ctmenu.js"></script>

    <script type="text/javascript" src="/ct2/html/images/foresee/foresee-trigger.js"></script>
<script type="text/javascript">
    $(window).load(function(){
        loadCTCommon();
        });
</script>
 


  <script type="text/javascript">
    ncbi_pingWithImage = true;
    ncbi_generateSid = true;
    ncbi_signinUrl = "//www.ncbi.nlm.nih.gov/portal/signin.fcgi?cmd=Nop";
    __ncbi_stat_url="//www.ncbi.nlm.nih.gov/stat";        
  </script>
  
  <meta name="ncbi_app" content="ctgov"/>
  <meta name="ncbi_db" content="ctgov"/>
  <meta name="ncbi_pdid" content="show_record"/>
  <meta name="ncbi_pcid" content="NCT00041938"/>
  <meta name="ncbi_ctreqid" content="RbmABGs4"/>
  <meta name="ncbi_ctsessid" content="SbmAAiE8"/>
  <meta name="ncbi_ctipid" content="IjUjl9rn"/>
  <meta name="ncbi_cthost" content="wp4"/>
  <meta name="ncbi_ctterm" content="&quot;Heart attack&quot; AND &quot;Los Angeles&quot;"/>
  <meta name="ncbi_ctrank" content="5"/>
  
</head>

<body class="js one-column"> 
<div id="skip"> <a href="#main-content">Skip to Main Content</a> </div>

<div id="wrapper">  
  
	<div id="header"> <a href="/ct2/home" style="border: none;"><img src='/ct2/html/ct3/images/ct.gov-logo.png' width='248' height='33' alt='ClinicalTrials.gov' /></a><br />
    <div id="tagline">A service of the U.S. National Institutes of Health</div>
		 
<div id="header-search">
	<p class="for-example">Example: "Heart attack" AND "Los Angeles"</p>
	<form method="get" action="/ct2/results" onsubmit="sendSearchPing(); return true;">
	<label for="header-search-query" >Search for studies:</label>
	<div><input id="header-search-query" type="text" name="term" value="" size="43" maxlength="250"/></div>
	<div><input name="Search" type="submit" value="Search" /></div>
	<input type="hidden" name="view" alt="Hidden" value="record"/>
</form>
	<div id="header-search-extras">
			<ul>
				<li class="first-item"><a href="/ct2/search/advanced">Advanced Search</a></li>
				<li><a href="/ct2/help/how-find/basic">Help</a></li>
				<li><a href="/ct2/search/browse?brwse=cond_cat">Studies by Topic</a></li>
				<li class="last-item"><a href="/ct2/about-studies/glossary">Glossary</a></li>
			</ul>
	</div>
</div>
   </div>



	<div id="global-nav">
		<ul class="sf-menu">
			<li class="first"><a href="/ct2/search/index">Find Studies</a>
			<ul>
                      <li                  ><a           href="/ct2/search">Basic Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Clinical Studies</a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Clinical Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Clinical Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies</a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources</a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About This Site</a>
			<ul>
                      <li                  ><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
		</ul>
    <div style="clear:both;"></div>
  </div>


<div id="utilities">
            <div id="text-size"> <a id="show-dropdown" href="/ct2/textsize-help"><span>Text Size</span></a>
               <ul id="dropdown">
                <li><a href="#" id="up">Make bigger</a></li>
                <li><a href="#" id="down">Make smaller</a></li>
                <li><a href="#" id="reset">Reset</a></li>
                <li class="close"><a href="#" id="close">close</a></li>
            </ul>
           </div>

</div>
<div id="breadcrumb">
	<ul class="horz-list">
		<li><a href="/ct2/home">Home</a></li>

		<li><a href="/ct2/search">Find Studies</a></li>
		<li><a href="/ct2/results?term=%22Heart+attack%22+AND+%22Los+Angeles%22&amp;view=record&amp;pg=1">Search Results</a></li>		<li class="last">Study Record Detail</li>
	</ul>
</div>


<div id="main-content">


        	<div id="search-results">
		<div class="results-summary">Trial record <strong>5 of 148</strong> for:
        &nbsp;&nbsp; &quot;Heart attack&quot; AND &quot;Los Angeles&quot;
        </div>
        <div class="results-nav">
        <a href="/ct2/show/record?term=%22Heart+attack%22+AND+%22Los+Angeles%22&amp;rank=4&amp;view=record" class="prev-link">Previous Study</a>         | <a href="/ct2/results?term=%22Heart+attack%22+AND+%22Los+Angeles%22&amp;view=record&amp;pg=1" class="return-link">Return to List</a> |
         <a href="/ct2/show/record?term=%22Heart+attack%22+AND+%22Los+Angeles%22&amp;rank=6&amp;view=record" class="next-link">Next Study</a> 		</div>
	</div>
	<h1>Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial</h1>
	<div id="trial-info-1" class="floater-50">

     


      
        <div  class="not-recruiting-status" >
      This study has been completed.
          </div>
        
        
      
        




                <div class="info-title">Sponsor:</div>
                <div class="info-text" id="sponsor"> Columbia University </div>


                <div class="info-title">Collaborator:</div>
                 				   <div class="info-text">National Institute of Neurological Disorders and Stroke (NINDS)</div> 				
                <div class="info-title">Information provided by (Responsible Party):</div>
                <div class="info-text">Shunichi Homma, Columbia University</div>


            </div>
               <div id="trial-info-2" class="floater-50">
                <div class="info-title">ClinicalTrials.gov Identifier:</div>
                <div class="identifier">NCT00041938</div>
                <div class="info-date">First received: July 19, 2002</div>
                <div class="info-date">Last updated:  August 29, 2014</div>
                <div class="info-date">Last verified:  August 2014 </div>
                <div class="info-date"> <a href="/ct2/archive/NCT00041938"
          title="Historical versions of study NCT00041938 on ClinicalTrials.gov Archive Site - opens in new window"
          onclick="openNewWindow('/ct2/archive/NCT00041938'); return false;">History of Changes</a> </div>
            </div>



<div id="tabs">
        <ul id="tab-links">
			<li id="full-text" ><a href="/ct2/show/study/NCT00041938?term=%22Heart+attack%22+AND+%22Los+Angeles%22&amp;rank=5&amp;view=record"  >Full Text View</a></li>
			<li id="tabular"     class="current"> Tabular View       </li>
			<li id="results"   ><a href="/ct2/show/results/NCT00041938?term=%22Heart+attack%22+AND+%22Los+Angeles%22&amp;rank=5&amp;view=record">Study Results</a></li>
			<li id="disclaimer"><a href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			<li id="howtoread"><a title="How to Read a Study Record - opens new window"  href="/ct2/help/how-read-study" onclick="openNewWindow('/ct2/help/how-read-study'); return false"
>How to Read a Study Record</a></li>
        </ul>
</div>  




<!-- field list -->
<div class="indent1">

  <br/>

  <table class="data_table" cellspacing="3" cellpadding="5" width="100%">
    <tr>
      <th class="header2 banner_color" align="left" valign="middle" style="height:3ex" colspan="2">Tracking Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">First Received Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top">July 19, 2002</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Last Updated Date </th>
            <td class="body3" valign="top">August 29, 2014</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Start Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top">October 2002</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Primary Completion Date </th>
            <td class="body3" valign="top">August 2011 &nbsp; (final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Current Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;August 29, 2014)</span></th>
            <td class="body3" valign="top">Event Rate Per 100 Patient Years for Composite Endpoint of Ischemic Stroke, Intracerebral Hemorrhage, or Death [&nbsp;Time&nbsp;Frame:&nbsp;From date of randomization until the date of the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to 6 years&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<div class="indent2" style="margin-top:1ex;">The time, in years, from randomization to the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years. Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</div></td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Original Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Change History </th>
            <td class="body3" valign="top"><a href="/ct2/archive/NCT00041938" onclick="openNewWindow('/ct2/archive/NCT00041938'); return false;">Complete list of historical versions of study NCT00041938 on ClinicalTrials.gov Archive Site</a></td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Current Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;August 29, 2014)</span></th>
            <td class="body3" valign="top">Event Rate Per 100 Patient-years for Composite Endpoint of Hospitalization for Heart Failure, Myocardial Infarction, Ischemic Stroke, Intracerebral Hemorrhage, or Death. [&nbsp;Time&nbsp;Frame:&nbsp;From randomization to the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years.&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<div class="indent2" style="margin-top:1ex;"><p style="margin-top:0ex; margin-bottom:1ex;">The time, in years, from date of randomization to the date of the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to 6 years.</p>
<p style="margin-top:0ex; margin-bottom:1ex;">Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</p></div></td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Original Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Current Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;August 29, 2014)</span></th>
            <td class="body3" valign="top"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Event Rate Per 100 Patient-years for Ischemic Stroke [&nbsp;Time&nbsp;Frame:&nbsp;From date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<div class="indent2" style="margin-top:1ex;">Time, in years, from date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</div></li>
<li style="margin:1ex 0.5ex">Event Rate Per 100 Patient-years for Intracerebral Hemorrhage [&nbsp;Time&nbsp;Frame:&nbsp;From date of randomization to date of intracerebral hemorrhage component of primary composite outcome, up to 6 years&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<div class="indent2" style="margin-top:1ex;">Time, in years, from date of randomization to date of intracerebral hemorrhage component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</div></li>
<li style="margin:1ex 0.5ex">Event Rate Per 100 Patient-years for Death [&nbsp;Time&nbsp;Frame:&nbsp;From date of randomization to date of death component of primary composite outcome, up to 6 years&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<div class="indent2" style="margin-top:1ex;">Time, in years, from date of randomization to date of death component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</div></li>
<li style="margin:1ex 0.5ex">Event Rate Per 100 Patient Years of Myocardial Infarction Component of Secondary Composite Outcome [&nbsp;Time&nbsp;Frame:&nbsp;From date of randomization to date of myocardial infarction component of secondary composite outcome, up to 6 years&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<div class="indent2" style="margin-top:1ex;">Time, in years, from date of randomization to date of myocardial infarction, up to 6 years. Includes only myocardial infarctions that occurred during follow-up, before any heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with myocardial infarction)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</div></li>
<li style="margin:1ex 0.5ex">Event Rate Per 100 Patient Years of Heart Failure Hospitalization Component of Secondary Composite Outcome. [&nbsp;Time&nbsp;Frame:&nbsp;From date of randomization to date of heart failure hospitalization component of secondary composite outcome, up to 6 years&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<div class="indent2" style="margin-top:1ex;">Time, in years, from date of randomization to date of heart failure hospitalization, up to 6 years. Includes hospitalizations for heart failure during follow-up that were not preceded by myocardial infarction. Event rate per 100 patient years = 100*(number of subjects with heart failure hospitalization)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</div></li>
<li style="margin:1ex 0.5ex">Event Rate Per 100 Patient Years of Ischemic Stroke Component of Secondary Composite Outcome [&nbsp;Time&nbsp;Frame:&nbsp;From date of randomization to date of ischemic stroke component of secondary composite outcome, up to 6 years&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<div class="indent2" style="margin-top:1ex;">Ischemic stroke component of secondary composite endpoint. Includes only ischemic strokes that were not preceded by a myocardial infarction or heart failure hospitalization. The number of ischemic strokes that are components of the secondary outcome does not therefore match the number of ischemic strokes that are components of the primary outcome. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25.</div></li>
<li style="margin:1ex 0.5ex">Event Rate Per 100 Patient Years of Intracerebral Hemorrhage Component of Secondary Composite Outcome [&nbsp;Time&nbsp;Frame:&nbsp;From date of randomization to date of intracerebral hemorrhage component of secondary composite outcome, up to 6 years&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<div class="indent2" style="margin-top:1ex;">Time, in years, from date of randomization to date of intracerebral hemorrhage component of secondary composite outcome. Includes only intracerebral hemorrhages not preceded by myocardial infarction or heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</div></li>
<li style="margin:1ex 0.5ex">Event Rate Per 100 Patient Years of Death Component of Secondary Composite Outcome [&nbsp;Time&nbsp;Frame:&nbsp;From date of randomization to date of death component of secondary composite outcome, up to 6 years&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<div class="indent2" style="margin-top:1ex;">Time, in years, from randomization to death component of secondary composite outcome. This measure counts only deaths that were not preceded by heart failure hospitalization, myocardial infarction, ischemic stroke, or intracerebral hemorrhage. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</div></li>
<li style="margin:1ex 0.5ex">Rate Per 100 Patient Years of Major Hemorrhage [&nbsp;Time&nbsp;Frame:&nbsp;From date of randomization until end of scheduled follow-up, up to 6 years&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<div class="indent2" style="margin-top:1ex;">Rate/100 patient-years of major hemorrhage. Includes all major hemorrhages in any patient. Major hemorrhage was defined as intracerebral, epidural, subdural, subarachnoid, spinal intramedullary, or retinal hemorrhage; any other bleeding causing a decline in the hemoglobin level of more than 2 g per deciliter in 48 hours; or bleeding requiring transfusion of 2 or more units of whole blood, hospitalization, or surgical intervention. Event rate per 100 patient years = 100*(number of major hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</div></li>
<li style="margin:1ex 0.5ex">Rate Per 100 Patient-years of Minor Hemorrhage. [&nbsp;Time&nbsp;Frame:&nbsp;From date of randomization until the end of scheduled follow-up, up to 6 years&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<div class="indent2" style="margin-top:1ex;">Rate per 100 patient years of minor hemorrhage. Includes all minor hemorrhages. Minor hemorrhage was defined as any non-major hemorrhage. Event rate per 100 patient years = 100*(number of minor hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25.</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Original Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color" align="left" valign="middle" style="height:3ex" colspan="2">Descriptive Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Brief Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top">Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Official Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top">Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Brief Summary </th>
            <td class="body3" valign="top"><p style="margin-top:0ex; margin-bottom:1ex;">The purpose of this study is to determine which of two treatments, Warfarin or aspirin, is better for preventing death and stroke in patients with poor heart function.</p>
    <p style="margin-top:0ex; margin-bottom:1ex;">We are now transitioning into the sub-analysis part of the WARCEF patient data.</p>
    <p style="margin-top:0ex; margin-bottom:1ex;">The study has recently completed data analysis for its Primary Aim. All randomized patients have completed their follow up. All study related procedure as per the protocol has been completed. We are now in the extension phase of the study to obtain more patient data to address further aims of the study. No new procedures are performed and data already in place at the sites will be collected (EKG and echocardiograms).</p>
    <p style="margin-top:0ex; margin-bottom:1ex;">The aims for this study extension are:</p>
    <ul style="margin-top:1ex; margin-bottom:1ex;">
      <li style="margin-top:0.7ex;">To assess progression of cardiac dysfunction over time among heart failure patients</li>
      <li style="margin-top:0.7ex;">To correlate prognosis with cardiac dysfunction</li>
    </ul></td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Detailed Description </th>
            <td class="body3" valign="top"><p style="margin-top:0ex; margin-bottom:1ex;">Warfarin has proven effective in patients with ischemic heart disease, especially in the reduction of stroke, death and re-infarction following myocardial infarction, and in the reduction of stroke in atrial fibrillation. Warfarin is the most promising unstudied intervention in patients with cardiac failure. This randomized, double-blind, multi-center study will define optimal antithrombotic therapy for patients with cardiac (heart) failure and patients with low ejection fraction (EF). EF is the proportion of left ventricular volume emptied during systole. It reliably measures left ventricular systolic function.</p>
    <p style="margin-top:0ex; margin-bottom:1ex;">With the rapidly increasing numbers of elderly patients with heart failure, this study has important public health implications. The study will determine which of two commonly used treatments Warfarin, an anticoagulant, or aspirin, a drug which affects platelet function is better for preventing death and stroke in patients with low ejection fraction.</p></td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Study Type&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top">Interventional</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Study Phase </th>
            <td class="body3" valign="top">Phase 3</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Study Design&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top">Allocation: Randomized<br/>Intervention Model: Parallel Assignment<br/>Masking: Double Blind (Subject, Investigator)<br/>Primary Purpose: Prevention</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Condition&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Heart Disease</li>
<li style="margin:1ex 0.5ex">Stroke</li>
<li style="margin:1ex 0.5ex">Ischemic Heart Disease</li>
<li style="margin:1ex 0.5ex"><span class="hit_syn">Myocardial Infarction</span></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Intervention&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Drug: aspirin
<div class="indent2" style="margin-top:0.5ex">325 mg per day</div></li>
<li style="margin:1ex 0.5ex">Drug: Warfarin
<div class="indent2" style="margin-top:0.5ex">INR 2.5-3.0; target INR 2.75</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Study Arm (s) </th>
            <td class="body3" valign="top"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Active Comparator: aspirin
<div class="indent2" style="margin-top:0.5ex">Aspirin: 325 mg per day</div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Drug: aspirin</div></li>
<li style="margin:1ex 0.5ex">Active Comparator: warfarin
<div class="indent2" style="margin-top:0.5ex">Warfarin: International Normalized Ratio (INR) 2.5-3.0; target INR 2.75</div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Drug: Warfarin</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Publications * </th>
            <td class="body3" valign="top"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex"><a class="study-link" href="/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR08OgCtWR08A6h9Ei4L3BUgWwNG0it." onclick="openNewWindow('/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR08OgCtWR08A6h9Ei4L3BUgWwNG0it.'); return false">Homma S, Thompson JL, Qian M, Ye S, Di Tullio MR, Lip GY, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Labovitz AJ, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD; WARCEF Investigators. Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. Circ Heart Fail. 2015 May;8(3):504-9. doi: 10.1161/CIRCHEARTFAILURE.114.001725. Epub 2015 Apr 7.</a></li>
<li style="margin:1ex 0.5ex"><a class="study-link" href="/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR08WgCBcKCnA6h9Ei4L3BUgWwNG0it." onclick="openNewWindow('/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR08WgCBcKCnA6h9Ei4L3BUgWwNG0it.'); return false">Shaffer JA, Thompson JL, Cheng B, Ye S, Lip GY, Mann DL, Sacco RL, Pullicino PM, Freudenberger RS, Graham S, Mohr JP, Labovitz AJ, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Di Tullio MR, Homma S; WARCEF Investigators. Association of quality of life with anticoagulant control in patients with heart failure: the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. Int J Cardiol. 2014 Dec 15;177(2):715-7.</a></li>
<li style="margin:1ex 0.5ex"><a class="study-link" href="/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0ROK4jOg4BA6h9Ei4L3BUgWwNG0it." onclick="openNewWindow('/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0ROK4jOg4BA6h9Ei4L3BUgWwNG0it.'); return false">Homma S, Thompson JL, Sanford AR, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Massie BM, Labovitz AJ, Di Tullio MR, Gabriel AP, Lip GY, Estol CJ, Lok DJ, Ponikowski P, Anker SD; WARCEF Investigators. Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial. Circ Heart Fail. 2013 Sep 1;6(5):988-97. doi: 10.1161/CIRCHEARTFAILURE.113.000372. Epub 2013 Jul 23.</a></li>
<li style="margin:1ex 0.5ex"><a class="study-link" href="/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0nLgCjaR48A6h9Ei4L3BUgWwNG0it." onclick="openNewWindow('/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0nLgCjaR48A6h9Ei4L3BUgWwNG0it.'); return false">Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012 May 17;366(20):1859-69. doi: 10.1056/NEJMoa1202299. Epub 2012 May 2.</a></li>
</ul>
</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        * &nbsp; Includes publications given by the data provider as well as publications
        identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
      </td>
    </tr>

    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color" align="left" valign="middle" style="height:3ex;" colspan="2">Recruitment Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Recruitment Status&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top">Completed</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Enrollment&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top">2305</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Completion Date </th>
            <td class="body3" valign="top">July 2014</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Primary Completion Date </th>
            <td class="body3" valign="top">August 2011 &nbsp; (final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Eligibility Criteria&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top"><p style="margin-top:0ex; margin-bottom:1ex;">Inclusion Criteria</p>
    <ul style="margin-top:1ex; margin-bottom:1ex;">
      <li style="margin-top:0.7ex;">Cardiac EF &lt;=35% by radionuclide ventriculography, left ventriculography or quantitive echocardiographic measurement or an echocardiographic Wall Motion Index of &lt;=1.2, within three months of enrollment. The patient's clinical cardiac state at enrollment should be similar to their state at the time of the qualifying echocardiogram. The qualifying left ventricular function measurement must be obtained at least three months after an MI, coronary bypass grafting, PTCA, and at least one month after pacemaker insertion. Patients scheduled for mitral valve repair should have qualifying echo after surgery.</li>
      <li style="margin-top:0.7ex;">Modified Rankin score &lt;=4.</li>
      <li style="margin-top:0.7ex;">Patient must be taking ACE inhibitors. If intolerant of ACE inhibitor, patient must be on angiotensin II receptor blockers or hydralazine and nitrates.</li>
      <li style="margin-top:0.7ex;">Patient is able to follow an outpatient protocol (requiring monthly blood tests and clinic visits every four months for the duration of the study) and is available by telephone.</li>
      <li style="margin-top:0.7ex;">Patient understands the purpose and requirements of the study, can make him/herself understood, and has provided informed consent.</li>
      <li style="margin-top:0.7ex;">Patients with recent stroke or TIA within twelve (12) months will be eligible to be included in the recent stroke (RS) subgroup.</li>
      <li style="margin-top:0.7ex;">Chronic CHF patients (NYHA I * IV) admitted to the hospital can be randomized prior to discharge if the patient is stable, taking oral medications for 24 hours and ambulatory at the time of discharge. Stable New York Heart Association Class IV patients will be eligible for randomization.</li>
    </ul>
    <p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria</p>
    <ul style="margin-top:1ex; margin-bottom:1ex;">
      <li style="margin-top:0.7ex;">The presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal AF, mechanical valve, endocarditis, intracardiac mobile or pedunculated thrombus, and valvular vegetation.</li>
      <li style="margin-top:0.7ex;">Cyanotic congenital heart disease, Eisenmenger's syndrome.</li>
      <li style="margin-top:0.7ex;">Decompensated heart failure.</li>
      <li style="margin-top:0.7ex;">Cardiac surgery, angioplasty, or MI within the past 3 months prior to randomization.</li>
      <li style="margin-top:0.7ex;">A contraindication to the use of either warfarin or aspirin, e.g. active peptic ulcer disease, active bleeding diathesis, platelets &lt;100,000*, hematocrit &lt;30, INR &gt;1.3 (if not on warfarin), clotting factor abnormality that increases the risk of bleeding, alcohol or substance abuse, severe gait instability, cerebral hemorrhage, systemic hemorrhage within the past year, severe liver impairment (AST &gt;3x normal*, cirrhosis), any condition requiring regular use of non-steroidal anti-inflammatory agents, allergy to aspirin or warfarin, uncontrolled severe hypertension (systolic pressure &gt;180 mm Hg or diastolic pressure &gt; 110 mm Hg), positive stool guaiac not attributable to hemorrhoids, creatinine &gt;3.0*. *on most recent test done within 30 days prior to randomization</li>
      <li style="margin-top:0.7ex;">Patient needs continuing therapy with intravenous heparin or low molecular weight heparin or a specific antiplatelet agent.</li>
      <li style="margin-top:0.7ex;">Dementia or psychiatric or physical problem that prevents the patient from following an outpatient program reliably.</li>
      <li style="margin-top:0.7ex;">Comorbid conditions that may limit survival to less than five years.</li>
      <li style="margin-top:0.7ex;">Pregnancy, or female of childbearing potential who is not sterilized or is not using a medically accepted form of contraception* (see procedure manual). *A pregnancy test is required for all women of childbearing age.</li>
      <li style="margin-top:0.7ex;">Enrollment in another study that would conflict with WARCEF.</li>
      <li style="margin-top:0.7ex;">Hospitalization for new diagnosis of onset CHF within the past one month or carotid endarterectomy or pacemaker insertion within the past one month prior to randomization .</li>
      <li style="margin-top:0.7ex;">Person under 18 years of age.</li>
    </ul></td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Gender </th>
            <td class="body3" valign="top">Both</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Ages </th>
            <td class="body3" valign="top">18 Years and older</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Accepts Healthy Volunteers </th>
            <td class="body3" valign="top">No</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Contacts&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top"><i style="color:#777777">Contact information is only displayed when the study is recruiting subjects</i></td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Listed Location Countries&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top">United States, &nbsp; Canada</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Removed Location Countries </th>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color" align="left" valign="middle" style="height:3ex;" colspan="2">Administrative Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">NCT Number&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top">NCT00041938</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Other Study ID Numbers&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top">AAAC1093, U01NS039143-01, R01NS39154, CRC</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Has Data Monitoring Committee </th>
            <td class="body3" valign="top">Yes</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Responsible Party </th>
            <td class="body3" valign="top">Shunichi Homma, Columbia University</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Study Sponsor&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top">Columbia University</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Collaborators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top">National Institute of Neurological Disorders and Stroke (NINDS)</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Investigators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3" valign="top"><table class="layout_table" cellpadding="0" cellspacing="0" border="0">
  <tr valign="top">
   <td style="padding-left:1em">Principal Investigator:</td>
   <td style="padding-left:1em">Shunichi Homma, M.D.</td>
   <td style="padding-left:1em">Principal Cardiologist, Associate Chief, Division of Cardiology, and Director, Echocardiography Laboratories Professor of Medicine</td>
   <td style="padding-left:1em"></td>
  </tr>
  <tr valign="top">
   <td style="padding-left:1em">Principal Investigator:</td>
   <td style="padding-left:1em">Seamus Thompson, PhD</td>
   <td style="padding-left:1em">Statistical PI: Clinical Professor of Biostatistics and Neurology</td>
   <td style="padding-left:1em"></td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Information Provided By </th>
            <td class="body3" valign="top">Columbia University</td>
          </tr>
        <tr>
      <th class="header3 banner_color" align="left" valign="top" width="15%">Verification Date </th>
            <td class="body3" valign="top">August 2014</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        <sup style="color:blue"> ICMJE </sup>&nbsp; &nbsp; Data element required by the
        <a href="http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html">
        International Committee of Medical Journal Editors</a> and the
        <a href="http://www.who.int/ictrp/network/trds/en/index.html">World Health Organization ICTRP</a>
      </td>
    </tr>

  </table>
  <br/>

</div>

<br/>


<div id="to-top"><a href="#wrapper">To Top</a></div>

	<div style="clear:both;"></div>
</div> 

      <div id="for-footer">
        <ul class="horz-list">
            <li><a    href="/ct2/help/for-patient">For Patients and Families</a></li>
            <li><a href="/ct2/help/for-researcher">For Researchers</a></li>
            <li><a     href="/ct2/help/for-manager">For Study Record Managers</a></li>
        </ul>
    </div>

<div id="footer-menu">
    <ul class="horz-list">
		<li><a href="/ct2/home" style="white-space:nowrap">Home</a></li>
		<li><a     href="/ct2/resources/rss" style="white-space:nowrap">RSS Feeds</a></li>
		<li><a         href="/ct2/sitemap" style="white-space:nowrap">Site Map</a></li>
		<li><a       href="/ct2/about-site/terms-conditions" style="white-space:nowrap">Terms and Conditions</a></li>
		<li><a href="/ct2/about-site/disclaimer#" style="white-space:nowrap">Disclaimer</a></li>
		<li><a        href="/ct2/helpdesk?hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT00041938%3Fterm%3D%2522Heart%2Battack%2522%2BAND%2B%2522Los%2BAngeles%2522%26rank%3D5%26view%3Drecord" style="white-space:nowrap">Contact NLM Help Desk</a></li>
	</ul>
</div>

</div>  
<div id="fine-print">
	<ul class="horz-list">
		<li                  ><a title="NLM copyright information - opens new window"  href="https://www.nlm.nih.gov/copyright.html" onclick="openNewWindow('https://www.nlm.nih.gov/copyright.html'); return false"
>Copyright</a></li>
		<li                  ><a title="NLM privacy policy - opens new window"  href="https://www.nlm.nih.gov/privacy.html" onclick="openNewWindow('https://www.nlm.nih.gov/privacy.html'); return false"
>Privacy</a></li>
		<li                  ><a title="NLM accessibility - opens new window"  href="https://www.nlm.nih.gov/accessibility.html" onclick="openNewWindow('https://www.nlm.nih.gov/accessibility.html'); return false"
>Accessibility</a></li>
		<li                  ><a title="NLM viewers and players - opens new window"  href="https://www.nlm.nih.gov/plugins.html" onclick="openNewWindow('https://www.nlm.nih.gov/plugins.html'); return false"
>Viewers & Players</a></li>
		<li                  ><a title="NIH Freedom of Information Act office - opens new window"  href="http://www.nih.gov/icd/od/foia/index.htm" onclick="openNewWindow('http://www.nih.gov/icd/od/foia/index.htm'); return false"
>Freedom of Information Act</a></li>
		<li class="last-item"><a title="USA.gov - opens new window"  href="http://www.usa.gov/" onclick="openNewWindow('http://www.usa.gov/'); return false"
>USA.gov</a></li>
	</ul>
    <ul class="horz-list">
       <li><a title="U.S. National Library of Medicine - opens new window"  href="https://www.nlm.nih.gov/" onclick="openNewWindow('https://www.nlm.nih.gov/'); return false"
>U.S. National Library of Medicine</a></li>
       <li><a title="U.S. National Institutes of Health - opens new window"  href="http://www.nih.gov/" onclick="openNewWindow('http://www.nih.gov/'); return false"
>U.S. National Institutes of Health</a></li>
       <li class="last-item"><a title="U.S. Department of Health and Human Services - opens new window"  href="https://www.hhs.gov/" onclick="openNewWindow('https://www.hhs.gov/'); return false"
>
            U.S. Department of Health and Human Services</a></li>
    </ul>
</div>

    <script type="text/javascript" src="/ct2/html/ct3/js/pinger.js"></script>

</body>
</html>
